Prolonged infusion of gemcitabine in advanced solid tumors: a phase-I-study.
BACKGROUND
Gemcitabine is a pro-drug that has to be phosphorylated to gemcitabine-triphosphate in order to exhibit its antineoplastic activity. This reaction involves the enzyme deoxycytidine kinase which is saturated at plasma concentrations following standard 30-min infusions. Pharmacological studies indicate that prolonged administration of gemcitabine might result in higher intracellular concentrations of active metabolites. This phase I trial was therefore initiated to determine the optimal dose of gemcitabine administered over 4 h in patients with advanced solid tumors.


METHODS
Patients were treated with gemcitabine as 4 h-infusion on day 1, 8 and 15 in 4 week intervals. The starting dose was 350 mg/m(2). Doses were escalated in 50 mg/m(2) increments.


RESULTS
Twenty-one patients were treated at doses ranging from 350 to 450 mg/m(2). The maximum tolerated dose was 400 mg/m(2) with neutropenia, thrombocytopenia, stomatitis and elevation of liver enzymes being dose limiting toxicities (DLTs). Hematologic and nonhematological toxicities were generally mild to moderate. Most common side effects were myelosuppression, nausea, elevation of liver enzymes and asthenia. Objective responses were noted in patients with hepatocellular carcinoma and cholangio-carcinoma.


CONCLUSIONS
In this phase I study of gemcitabine as 4h-infusion, DLTs were neutropenia, thrombocytopenia, stomatitis and elevation of liver enzymes. The recommended dose for phase II studies is 400 mg/m(2).
Schmid
Peter
P
Medizinische Klinik mit Schwerpunkt Onkologie und Hämatologie, Charité Campus Mitte, Humboldt Universität zu Berlin, 10117 Berlin, Germany. peter.schmid@charite.de
Schweigert
Marcus
M
Beinert
Thomas
T
Flath
Bernd
B
Sezer
Orhan
O
Possinger
Kurt
K
D000328:Adult; D000368:Aged; D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D003841:Deoxycytidine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D007262:Infusions, Intravenous; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000097:blood / Q000145:classification / Q000188:drug therapy*; D000093542:Gemcitabine
D000964:Antimetabolites, Antineoplastic; D003841:Deoxycytidine; D000093542:Gemcitabine
Cancer Chemother Pharmacol. 1991;27(4):258-62
1998982
J Clin Oncol. 1991 Mar;9(3):491-8
1999720
Cancer Chemother Pharmacol. 1996;38(4):335-42
8674156
Semin Oncol. 1995 Aug;22(4 Suppl 11):3-10
7481842
Invest New Drugs. 1997;15(4):331-41
9547676
J Clin Oncol. 1994 Aug;12(8):1527-31
8040662
Anticancer Drugs. 1999 Jul;10(6):525-31
10885899
Invest New Drugs. 1998-1999;16(3):275-8
10360609
Semin Oncol. 1995 Aug;22(4 Suppl 11):19-25
7481840
Anticancer Drugs. 1995 Dec;6 Suppl 6:27-32
8718422
Ann Oncol. 1998 Sep;9(9):1003-8
9818075
Invest New Drugs. 1997;15(2):115-21
9220290
Anticancer Drugs. 2001 Oct;12(9):713-7
11593051
Anticancer Drugs. 1999 Aug;10(7):625-31
10507311
Cancer Res. 1990 Nov 1;50(21):6823-6
2208147
Semin Oncol. 1995 Aug;22(4 Suppl 11):11-8
7481839
Ann Oncol. 2000 Oct;11(10):1309-11
11106121
Cancer Chemother Pharmacol. 2002 Jul;50(1):80-3
12111116